Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2

被引：0
|
作者：
Shvartsbart, Artem
Ito, Koichi
Rager, Joseph
Hulse, Michael
Agarwal, Anjana
Vykuntam, Komali
Burtell, Jessica
Wang, Min
Kurian, Justin
Cowart, Miles
Cote, Joy
Stahl, Nick
Sivakumar, Monisha
Reichelderfer, Anthony
Carter, Jack
Grego, Alexander
Moore, Andrew
Bhagwat, Neha
Kuskovsky, Ross
Ganesan, Shanthi
Ruepp, Stefan
Emm, Tom
Pitis, Philip
Basch, Corey
Bersch, Klare
Pan, Yongchun
Mei, Song
Leal, Raul
Rose, John
Roth, Dani
Xu, Chaoyi
Cao, Ganfeng
Vaddi, Kris
Lee, Sang Hyun
Geeganage, Sandy
Combs, Andrew
Scherle, Peggy
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4503
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Discovery of NKT3964: a first-in-class, highly potent and selective, orally bioavailable CDK2 PROTAC degrader for cancer therapy
    Geng, J.
    Liu, K.
    Yu, Z.
    Sun, W.
    Yeh, Y. T.
    Wei, H.
    Li, W.
    Lu, J.
    Deng, J.
    Yang, C.
    Geng, L.
    Luo, X.
    Liu, Z.
    Gao, Z.
    Lou, Y.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S8 - S8
  • [22] Development of potent, orally bioavailable, and highly selective LRRK2 PROTAC® degrader molecules as potential disease modifying therapeutics for Parkinson's disease
    Kelly, K.
    Meredith, J.
    Kimmel, L.
    Sparks, S.
    DeSantis, A.
    Bryce, D.
    Wilson, R.
    Corradi, J.
    Keenan, S.
    Cadelina, G.
    Pizzano, J.
    Cacace, A.
    MOVEMENT DISORDERS, 2023, 38 : S611 - S611
  • [23] The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
    Liang, Yanke
    Sowa, Mathew E.
    Jackson, Katrina L.
    Simard, Jeffrey R.
    Kreger, Bridget
    Li, Ping
    Poling, Laura
    Baddour, Joelle
    Good, Andrew
    Huang, Hongwei
    Eron, Scott
    Nasveschuk, Christopher G.
    Yu, Robert
    Fitzgerald, Mark
    Garza, Victoria
    O'Shea, Morgan W.
    Veits, Gesine
    Yap, Jeremy Y.
    Moustakim, Moses
    Hart, Ashley
    Agafonov, Roman V.
    Sarkissian, Grace
    Patel, Joe S.
    Deibler, Richard
    Cole, Kyle S.
    Cocozziello, David
    Rahman, Fazlur
    Phillips, Andrew J.
    Norton, Elizabeth
    Crystal, Adam S.
    Pollock, Roy M.
    Fisher, Stewart L.
    CANCER RESEARCH, 2023, 83 (07)
  • [24] GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER plus Breast Cancer
    Liang, Jun
    Zbieg, Jason R.
    Blake, Robert A.
    Chang, Jae H.
    Daly, Stephen
    DiPasquale, Antonio G.
    Friedman, Lori S.
    Gelzleichter, Thomas
    Gill, Matthew
    Giltnane, Jennifer M.
    Goodacre, Simon
    Guan, Jane
    Hartman, Steven J.
    Ingalla, Ellen Rei
    Kategaya, Lorn
    Kiefer, James R.
    Kleinheinz, Tracy
    Labadie, Sharada S.
    Lai, Tommy
    Li, Jun
    Liao, Jiangpeng
    Liu, Zhiguo
    Mody, Vidhi
    McLean, Neville
    Metcalfe, Ciara
    Nannini, Michelle A.
    Oeh, Jason
    O'Rourke, Martin G.
    Ortwine, Daniel F.
    Ran, Yingqing
    Ray, Nicholas C.
    Roussel, Fabien
    Sambrone, Amy
    Sampath, Deepak
    Schutt, Leah K.
    Vinogradova, Maia
    Wai, John
    Wang, Tao
    Wertz, Ingrid E.
    White, Jonathan R.
    Yeap, Siew Kuen
    Young, Amy
    Zhang, Birong
    Zheng, Xiaoping
    Zhou, Wei
    Zhong, Yu
    Wang, Xiaojing
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (16) : 11841 - 11856
  • [25] Discovery of a highly potent and orally bioavailable selective estrogen receptor degrader (SERD) GNE-149 for ER-positive breast cancer
    Liang, Jun
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [26] Development of Highly Potent, G-Protein Pathway Biased, Selective, and Orally Bioavailable GPR84 Agonists
    Wang, Pinqi
    Raja, Arun
    Luscombe, Vincent B.
    Bataille, Carole J. R.
    Lucy, Daniel
    Rogga, Vanessa V.
    Greaves, David R.
    Russell, Angela J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 67 (01) : 110 - 137
  • [27] Pharmacological characterization of the selective, orally bioavailable, potent mTORC1/2 inhibitor PQR620
    Beaufils, Florent
    Rageot, Denise
    Melone, Anna
    Sele, Alexander
    Lang, Marc
    Mestan, Juergen
    Ettlin, Robert A.
    Hillmann, Petra
    Cmiljanovic, Vladimir
    Walter, Carolin
    Singer, Elisabeth
    Nguyen, Hoa H. P.
    Hebeisen, Paul
    Fabbro, Dorian
    Wymann, Matthias P.
    CANCER RESEARCH, 2016, 76
  • [28] Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3
    Gayine, Paul R.
    Mooney, Lorraine
    Kilgour, Elaine
    Thomas, Andrew P.
    Al-Kadhimi, Katherine
    Beck, Sarah
    Coleman, Tanya
    Baker, Dawn
    Mellor, Martine J.
    Brooks, Nigel A. N.
    Klinowska, Teresa
    CANCER RESEARCH, 2011, 71
  • [29] Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
    Lal, Shruti
    Bhola, Neil E.
    Sun, Bee-Chun
    Chen, Yuping
    Huang, Tom
    Morton, Vivian
    Chen, Kevin X.
    Xia, Shanghua
    Zhang, Haoyu
    Parikh, Nehal S.
    Ye, Qiuping
    Veiby, O. Petter
    Bellovin, David I.
    Ji, Yuhua
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (09): : 1731 - 1742
  • [30] Discovery and characterization of ZL-2201, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitor
    Lal, Shruti
    Sun, Bee-Chun
    Chen, Yuping
    Huang, Tom
    Bhola, Neil
    Morton, Vivian
    Chen, Kevin
    Xia, Shanghua
    Zhang, Haoyu
    Ye, Qiuping
    Veiby, Petter
    Bellovin, David I.
    Ji, Yuhua
    CANCER RESEARCH, 2022, 82 (12)
12345